Fiyinfolu Balogun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fiyinfolu Balogun has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
- Eileen Mary O'Reilly
Weill Cornell Medicine
38 shared publications - Wungki Park
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
38 shared publications - Christine Iacobuzio-Donahue
The David M Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY
36 shared publications - Marsha Reyngold
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
32 shared publications - Chaitanya Bandlamudi
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, NY
30 shared publications - Anna M. Varghese
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
29 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Pancreatic Cancer: Translating Tumor Biology into Actionability
RAS allele-specific targeted trials in pancreatic cancer—select completed and ongoing.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Pancreatic Cancer: Translating Tumor Biology into Actionability
RAS allele-specific targeted trials in pancreatic cancer—select completed and ongoing.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Pancreatic Cancer: Translating Tumor Biology into Actionability
RAS multi-allele and immune-targeted trials in pancreatic cancer—select completed and ongoing.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Pancreatic Cancer: Translating Tumor Biology into Actionability
RAS multi-allele and immune-targeted trials in pancreatic cancer—select completed and ongoing.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Pancreatic Cancer: Translating Tumor Biology into Actionability
MAPK pathway targeting for pancreatic cancer. [Created in BioRender. Rubenstein, D. (2025) https://BioRender.com/27s6pcf.]
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Pancreatic Cancer: Translating Tumor Biology into Actionability
MAPK pathway targeting for pancreatic cancer. [Created in BioRender. Rubenstein, D. (2025) https://BioRender.com/27s6pcf.]
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Pancreatic Cancer: Translating Tumor Biology into Actionability
Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers and has a very poor prognosis. Ten to 15% are staged as resectable at diagnosis, and 5% to 15% downstaged with therapy to where surgery is feasible. Chemotherapy is a mainstay for all stages of PDAC. Targeted therapies are available for patients with select but expanding actionable genomic alterations. The tumor microenvironment provides a dense stroma with an immunosuppressive milieu that contributes to inherent treatment resistance of PDAC. Herein, we review current management of PDAC with a focus on emerging treatment paradigms, including targeted and immunomodulatory agents.Significance:PDAC is a complex disease with unique genomic, immunologic, and clinical features. Recent developments in understanding of the pathobiology of this disease are translating into targeted and immunomodulatory therapies that will alter treatment paradigms and improve outcomes for this recalcitrant malignancy.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Pancreatic Cancer: Translating Tumor Biology into Actionability
Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers and has a very poor prognosis. Ten to 15% are staged as resectable at diagnosis, and 5% to 15% downstaged with therapy to where surgery is feasible. Chemotherapy is a mainstay for all stages of PDAC. Targeted therapies are available for patients with select but expanding actionable genomic alterations. The tumor microenvironment provides a dense stroma with an immunosuppressive milieu that contributes to inherent treatment resistance of PDAC. Herein, we review current management of PDAC with a focus on emerging treatment paradigms, including targeted and immunomodulatory agents.Significance:PDAC is a complex disease with unique genomic, immunologic, and clinical features. Recent developments in understanding of the pathobiology of this disease are translating into targeted and immunomodulatory therapies that will alter treatment paradigms and improve outcomes for this recalcitrant malignancy.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Pancreatic Cancer: Translating Tumor Biology into Actionability
Mechanisms of KRAS inhibitor/degrader.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Pancreatic Cancer: Translating Tumor Biology into Actionability
Mechanisms of KRAS inhibitor/degrader.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Pancreatic Cancer: Translating Tumor Biology into Actionability
Current treatment regimens for pancreatic cancer.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Pancreatic Cancer: Translating Tumor Biology into Actionability
Current treatment regimens for pancreatic cancer.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (7) , 1262-1279
Pancreatic Cancer: Translating Tumor Biology into Actionability
Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers and has a very poor prognosis. Ten to 15% are staged as resectable at diagnosis, and 5% to 15% downstaged with therapy to where surgery is feasible. Chemotherapy is a mainstay for all stages of PDAC. Targeted therapies are available for patients with select but expanding actionable genomic alterations. The tumor microenvironment provides a dense stroma with an immunosuppressive milieu that contributes to inherent treatment resistance of PDAC. Herein, we review current management of PDAC with a focus on emerging treatment paradigms, including targeted and immunomodulatory agents. Significance: PDAC is a complex disease with unique genomic, immunologic, and clinical features. Recent developments in understanding of the pathobiology of this disease are translating into targeted and immunomodulatory therapies that will alter treatment paradigms and improve outcomes for this recalcitrant malignancy.
- 1 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (7) , 1262-1279
Open AccessPancreatic Cancer: Translating Tumor Biology into Actionability
Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers and has a very poor prognosis. Ten to 15% are staged as resectable at diagnosis, and 5% to 15% downstaged with therapy to where surgery is feasible. Chemotherapy is a mainstay for all stages of PDAC. Targeted therapies are available for patients with select but expanding actionable genomic alterations. The tumor microenvironment provides a dense stroma with an immunosuppressive milieu that contributes to inherent treatment resistance of PDAC. Herein, we review current management of PDAC with a focus on emerging treatment paradigms, including targeted and immunomodulatory agents. Significance: PDAC is a complex disease with unique genomic, immunologic, and clinical features. Recent developments in understanding of the pathobiology of this disease are translating into targeted and immunomodulatory therapies that will alter treatment paradigms and improve outcomes for this recalcitrant malignancy.
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (2) , 101
Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report
Background: Although pancreatic cancer is an aggressive malignancy with a propensity for metastatic spread, brain metastases (BrMs) remain exceptionally rare (Case Description: We present a case of BrMs in a 69-year-old pancreatic cancer patient. This patient initially presented with a history of chronic pancreatitis, abdominal and back pain, and significant weight loss. After the diagnostic biopsy confirmed pancreatic cancer, the patient was enrolled onto the PASS-01 clinical trial and was treated with standard of care chemotherapy before progressing and developing BrMs 10 months after cancer diagnosis. The BrMs were removed via craniotomy, and the patient also underwent radiation and chemotherapy before enrolling onto the MYTHIC clinical trial for PKMYT1 inhibitor, RP-6306. Successful generation of a BrM-derived organoid line enabled high-throughput drug screening, which recapitulated the patient’s clinical resistance to standard therapies [gemcitabine/nab-paclitaxel, 5-fluorouracil (5-FU)], and showed sensitivity to afatinib, everolimus and RMC-6236. Conclusions: This case report demonstrates the importance of precision medicine to characterize patient tumor and identify actionable targets and potential therapies. Physicians should also be aware that KRAS wild-type pancreatic cancer with atypical amplifications is likely to exhibit unique metastatic tropisms. Finally, we suggest that patient-derived organoids pharmacotyping can mirror clinical drug responses and help evaluate therapeutic avenues for patient treatment.
- 1 April 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (2) , 101
Open AccessBrain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report
Background: Although pancreatic cancer is an aggressive malignancy with a propensity for metastatic spread, brain metastases (BrMs) remain exceptionally rare (Case Description: We present a case of BrMs in a 69-year-old pancreatic cancer patient. This patient initially presented with a history of chronic pancreatitis, abdominal and back pain, and significant weight loss. After the diagnostic biopsy confirmed pancreatic cancer, the patient was enrolled onto the PASS-01 clinical trial and was treated with standard of care chemotherapy before progressing and developing BrMs 10 months after cancer diagnosis. The BrMs were removed via craniotomy, and the patient also underwent radiation and chemotherapy before enrolling onto the MYTHIC clinical trial for PKMYT1 inhibitor, RP-6306. Successful generation of a BrM-derived organoid line enabled high-throughput drug screening, which recapitulated the patient’s clinical resistance to standard therapies [gemcitabine/nab-paclitaxel, 5-fluorouracil (5-FU)], and showed sensitivity to afatinib, everolimus and RMC-6236. Conclusions: This case report demonstrates the importance of precision medicine to characterize patient tumor and identify actionable targets and potential therapies. Physicians should also be aware that KRAS wild-type pancreatic cancer with atypical amplifications is likely to exhibit unique metastatic tropisms. Finally, we suggest that patient-derived organoids pharmacotyping can mirror clinical drug responses and help evaluate therapeutic avenues for patient treatment.
- Top Cited PapersOpen Access
- 25 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1783-1793
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial
Homologous recombination deficiency (HRD) arising from BRCA1 or BRCA2 or PALB2 mutations confers sensitivity to platinum chemotherapy and PARP inhibition in pancreatic cancer (PC) and may enable prolonged disease control with immune checkpoint blockade (ICB). The phase 2 POLAR trial evaluated maintenance pembrolizumab plus olaparib following platinum-based chemotherapy in biomarker-stratified metastatic PC. Sixty-three participants were enrolled into three cohorts: cohort A ( BRCA1 / BRCA2 -mutated or PALB2 -mutated HRD, n = 33), cohort B (non-core HRD, n = 15) and cohort C (platinum sensitive, HRD-wild type, n = 15). Cohort A used a two-stage design with co-primary endpoints of at least 43% Response Evaluation Criteria in Solid Tumors (RECIST) objective response rate (ORR) and at least 77% 6-month progression-free survival (PFS) rate. Among RECIST-evaluable participants in cohort A ( n = 20), ORR was 35% (95% confidence interval (CI): 15−59%), whereas 6-month PFS rate in the full cohort ( n = 33) was 64% (95% CI: 49−82%), not meeting the primary endpoint. At a median follow-up of 37 months (95% CI: 27−47), median PFS and overall survival (OS) for cohort A were 8.3 (95% CI: 5.3−not reached (NR)) and 28 (95% CI: 12−NR) months, with 2-year and 3-year OS rates of 56% (95% CI: 41−76%) and 44% (95% CI: 28−69%), respectively. In cohorts B and C, ORR was 8% (95% CI: 0−38%) and 14% (95% CI: 2%-43%); median PFS was 4.8 (95% CI: 4.0−12) and 3.3 (95% CI: 1.9−4.8) months; and median OS was 18 (95% CI: 13−NR) and 10 (95% CI: 8.9−24) months, respectively. Preplanned translational analyses showed that circulating tumor DNA response, increased tumor-infiltrating lymphocytes and enrichment of frameshift indel neoantigens were associated with durable clinical benefit. These data suggest that a subset of HRD PC may derive prolonged benefit from PARP-ICB maintenance and support further development of biomarker-guided precision immunotherapy strategies in PC. ClinicalTrials.gov identifier: NCT04666740 .
- 25 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1783-1793
Top Cited PapersOpen AccessPembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial
Homologous recombination deficiency (HRD) arising from BRCA1 or BRCA2 or PALB2 mutations confers sensitivity to platinum chemotherapy and PARP inhibition in pancreatic cancer (PC) and may enable prolonged disease control with immune checkpoint blockade (ICB). The phase 2 POLAR trial evaluated maintenance pembrolizumab plus olaparib following platinum-based chemotherapy in biomarker-stratified metastatic PC. Sixty-three participants were enrolled into three cohorts: cohort A ( BRCA1 / BRCA2 -mutated or PALB2 -mutated HRD, n = 33), cohort B (non-core HRD, n = 15) and cohort C (platinum sensitive, HRD-wild type, n = 15). Cohort A used a two-stage design with co-primary endpoints of at least 43% Response Evaluation Criteria in Solid Tumors (RECIST) objective response rate (ORR) and at least 77% 6-month progression-free survival (PFS) rate. Among RECIST-evaluable participants in cohort A ( n = 20), ORR was 35% (95% confidence interval (CI): 15−59%), whereas 6-month PFS rate in the full cohort ( n = 33) was 64% (95% CI: 49−82%), not meeting the primary endpoint. At a median follow-up of 37 months (95% CI: 27−47), median PFS and overall survival (OS) for cohort A were 8.3 (95% CI: 5.3−not reached (NR)) and 28 (95% CI: 12−NR) months, with 2-year and 3-year OS rates of 56% (95% CI: 41−76%) and 44% (95% CI: 28−69%), respectively. In cohorts B and C, ORR was 8% (95% CI: 0−38%) and 14% (95% CI: 2%-43%); median PFS was 4.8 (95% CI: 4.0−12) and 3.3 (95% CI: 1.9−4.8) months; and median OS was 18 (95% CI: 13−NR) and 10 (95% CI: 8.9−24) months, respectively. Preplanned translational analyses showed that circulating tumor DNA response, increased tumor-infiltrating lymphocytes and enrichment of frameshift indel neoantigens were associated with durable clinical benefit. These data suggest that a subset of HRD PC may derive prolonged benefit from PARP-ICB maintenance and support further development of biomarker-guided precision immunotherapy strategies in PC. ClinicalTrials.gov identifier: NCT04666740 .
- Open Access
POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer
Pancreatic cancer (PC) is broadly resistant to immune checkpoint blockade, although a subset of homologous recombination-deficient (HRD) tumors exhibits durable immune engagement. The genomic features that distinguish these immune-responsive tumors from immune-inert HRD tumors remain poorly understood. Here we identify a microhomology-mediated end joining (MMEJ) repair scar, the MMEJ Deletion Footprint (MDF), as a genomic readout of POLQ-associated error-prone repair that enriches for frameshift indels. Across the multi-omic discovery cohort integrating tumor genomics, single-nucleus transcriptomics and spatial immune profiling, MDF-high HRD PC exhibited increased frameshift-indel-derived neoantigens and interferon programs. MDF was further associated with remodeling of the myeloid compartment toward MHC II-high dendritic cell-like antigen-presenting macrophage states and the immune synapse architecture marked by increased spatial interaction between APC-like macrophages and cytotoxic CD8 + T cells. These tissue-level features aligned with a functional trajectory shift of CD8 + T cells, consistent with effective anti-tumor immunity and was associated with favorable clinical outcomes of patients. Together, our findings position MMEJ-linked repair scarring as actionable biology that connects an HRD genotype to immune organization and suggests rational immunotherapy combinations that may enhance antigen presentation and myeloid activation to extend durable benefit in HRD-lineage cancers.
Open AccessPOLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer
Pancreatic cancer (PC) is broadly resistant to immune checkpoint blockade, although a subset of homologous recombination-deficient (HRD) tumors exhibits durable immune engagement. The genomic features that distinguish these immune-responsive tumors from immune-inert HRD tumors remain poorly understood. Here we identify a microhomology-mediated end joining (MMEJ) repair scar, the MMEJ Deletion Footprint (MDF), as a genomic readout of POLQ-associated error-prone repair that enriches for frameshift indels. Across the multi-omic discovery cohort integrating tumor genomics, single-nucleus transcriptomics and spatial immune profiling, MDF-high HRD PC exhibited increased frameshift-indel-derived neoantigens and interferon programs. MDF was further associated with remodeling of the myeloid compartment toward MHC II-high dendritic cell-like antigen-presenting macrophage states and the immune synapse architecture marked by increased spatial interaction between APC-like macrophages and cytotoxic CD8 + T cells. These tissue-level features aligned with a functional trajectory shift of CD8 + T cells, consistent with effective anti-tumor immunity and was associated with favorable clinical outcomes of patients. Together, our findings position MMEJ-linked repair scarring as actionable biology that connects an HRD genotype to immune organization and suggests rational immunotherapy combinations that may enhance antigen presentation and myeloid activation to extend durable benefit in HRD-lineage cancers.